Microbot Medical Enters Agreement with Sanmina to Manufacture Liberty System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Microbot Medical has entered into a letter of agreement with Sanmina Corporation to manufacture the Liberty System. The company believes it is necessary to expand its manufacturing capacity to meet expected demand from existing and new accounts as well as to support its cost reduction strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.930
Low
5.50
Averages
8.75
High
12.00
Current: 1.930
Low
5.50
Averages
8.75
High
12.00
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Microbot Medical Reports Over 100% Revenue Growth in Q2 2026
- Significant Revenue Growth: Microbot Medical announced that its Q2 2026 revenue grew over 100% from Q1, driven by the full U.S. launch of the LIBERTY® Endovascular Robotic System on April 13, indicating strong market demand and product acceptance.
- Customer Base Expansion: The company added new health system customers across Massachusetts, North Carolina, Michigan, and Pennsylvania, further solidifying its influence in the U.S. market and laying the groundwork for future sales growth.
- Sales Network Expansion: Microbot expanded its U.S. sales network from 4 to 8 territories and expects to reach 12 territories by year-end, a strategic move that will enhance market penetration and customer coverage.
- International Market Development: The company received regulatory clearance for the LIBERTY System from Israeli authorities, marking its first approval outside the U.S., while the addition of a second manufacturing site will support future demand and margin expansion, reflecting positive progress in its globalization strategy.
See More
Microbot Medical Partners with Sanmina for LIBERTY System Manufacturing
- Manufacturing Capacity Expansion: Microbot Medical has signed an agreement with leading manufacturing solutions provider Sanmina to expand production capacity for the LIBERTY® system, which is expected to significantly enhance the company's competitiveness in both U.S. and international markets as demand continues to rise.
- International Market Progress: With recent clearance in Israel and ongoing efforts to obtain CE Mark, Microbot is gaining momentum in international markets, which not only helps in acquiring new customers but also increases usage among existing clients, thereby driving sales growth.
- Cost Efficiency Improvement: The partnership with Sanmina is expected to improve operational efficiencies, reduce production costs, and expand gross margins, which is crucial for the company's sustainable development in the coming years.
- Market Demand Response: As the utilization of the LIBERTY system increases in the Eastern U.S., Microbot plans to expand into the Western market later this year, ensuring that the long-term partnership with Sanmina effectively addresses the anticipated growth in customer demand.
See More
Microbot Medical Wins Innovative Start-Up Award for LIBERTY System
- Award Recognition: Microbot Medical has been awarded the Innovative Start-Up Award from Surgical Robotics Technology (SRT) for its LIBERTY® Endovascular Robotic System, highlighting its significant advancements and potential impact in the medical technology sector.
- Increased Market Adoption: Since its full market release in April 2026, the LIBERTY System has been widely utilized at leading academic centers across states like New York, Pennsylvania, and Florida, indicating its growing importance in endovascular procedures.
- Unique Technology: LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system designed for precise vascular navigation, aiming to enhance safety and efficiency while reducing radiation exposure and physical strain during procedures.
- Strategic Future Focus: CEO Harel Gadot emphasized that Microbot Medical will continue to focus on expanding the adoption of the LIBERTY System and executing its commercial strategy, demonstrating a strong commitment to shaping the future of endovascular care through innovation.
See More
Microbot Medical Expands Footprint in Northeast U.S.
- Market Expansion: Microbot Medical's adoption of the LIBERTY System by a Pennsylvania academic center marks a significant increase in its market penetration in the Northeast U.S., now boasting multiple hospital clients across seven states, reflecting the effectiveness of its commercial efforts.
- Growing Customer Base: The new client operates multiple hospitals and multispecialty centers in Pennsylvania and New Jersey, becoming the second customer with facilities spanning two states, indicating the company's increasing influence in densely populated markets and further solidifying its market position.
- Sales Territory Plans: Following the full market release of the LIBERTY System, the company plans to expand its sales territory to the West Coast, demonstrating confidence in future growth and strategic positioning in new markets.
- Federal Healthcare System Collaboration: The agreement to expand access to the LIBERTY System across U.S. federal healthcare systems, including those serving veterans and military patients, further enhances adoption rates among existing and new accounts, supporting the company's commercialization strategy.
See More
Microbot Medical Expands LIBERTY System Adoption in Michigan
- Market Expansion: Microbot Medical announced the adoption of its LIBERTY® Endovascular Robotic System by one of the largest healthcare systems in Michigan, marking a significant acceleration in the system's rollout across the Midwest U.S., reflecting growing recognition among health systems for advanced robotic solutions.
- Increasing Demand: With approximately 2.5 million peripheral endovascular procedures performed annually in the U.S., Microbot believes this ongoing market expansion indicates a rising demand for integrating robotic technology into routine vascular care, suggesting strong future growth potential for the company.
- Regulatory Approval: The LIBERTY System recently received regulatory approval from the Israeli Ministry of Health's AMAR Division, allowing the company to market and sell the system in Israel, which not only broadens its market reach but also enhances its global business flexibility.
- Strategic Positioning: CEO Harel Gadot stated that the expansion of the LIBERTY System enhances procedural workflow efficiency while supporting physician well-being, further solidifying Microbot Medical's market position in the medical robotics sector.
See More
Microbot Medical Secures First Customer in North Carolina
- Market Expansion: Microbot Medical has successfully secured its first customer in North Carolina, marking a significant broadening of its LIBERTY® Endovascular Robotic System's penetration in the Southeast and Mid-Atlantic regions, indicating strong growth potential in the medical device sector.
- Client Network: The new customer operates a multi-hospital network that provides state-of-the-art patient care across the state, further validating the unique advantages of the LIBERTY system and likely attracting more healthcare systems to consider its adoption.
- Commercial Strategy Execution: The addition of the North Carolina account is viewed as a significant advancement in Microbot's ongoing commercial strategy, with CEO Harel Gadot noting a rapid increase in new accounts following the full market release, reflecting robust market demand.
- Future Outlook: The company plans to penetrate other major metropolitan markets, aiming to attract leading academic institutions in the U.S. to adopt the LIBERTY system, which is expected to drive future revenue growth and enhance market share.
See More
Microbot Medical Reports Over 100% Revenue Growth in Q2 2026
- Significant Revenue Growth: Microbot Medical announced that its Q2 2026 revenue grew over 100% from Q1, driven by the full U.S. launch of the LIBERTY® Endovascular Robotic System on April 13, indicating strong market demand and product acceptance.
- Customer Base Expansion: The company added new health system customers across Massachusetts, North Carolina, Michigan, and Pennsylvania, further solidifying its influence in the U.S. market and laying the groundwork for future sales growth.
- Sales Network Expansion: Microbot expanded its U.S. sales network from 4 to 8 territories and expects to reach 12 territories by year-end, a strategic move that will enhance market penetration and customer coverage.
- International Market Development: The company received regulatory clearance for the LIBERTY System from Israeli authorities, marking its first approval outside the U.S., while the addition of a second manufacturing site will support future demand and margin expansion, reflecting positive progress in its globalization strategy.
See More
Microbot Medical Partners with Sanmina for LIBERTY System Manufacturing
- Manufacturing Capacity Expansion: Microbot Medical has signed an agreement with leading manufacturing solutions provider Sanmina to expand production capacity for the LIBERTY® system, which is expected to significantly enhance the company's competitiveness in both U.S. and international markets as demand continues to rise.
- International Market Progress: With recent clearance in Israel and ongoing efforts to obtain CE Mark, Microbot is gaining momentum in international markets, which not only helps in acquiring new customers but also increases usage among existing clients, thereby driving sales growth.
- Cost Efficiency Improvement: The partnership with Sanmina is expected to improve operational efficiencies, reduce production costs, and expand gross margins, which is crucial for the company's sustainable development in the coming years.
- Market Demand Response: As the utilization of the LIBERTY system increases in the Eastern U.S., Microbot plans to expand into the Western market later this year, ensuring that the long-term partnership with Sanmina effectively addresses the anticipated growth in customer demand.
See More
Microbot Medical Wins Innovative Start-Up Award for LIBERTY System
- Award Recognition: Microbot Medical has been awarded the Innovative Start-Up Award from Surgical Robotics Technology (SRT) for its LIBERTY® Endovascular Robotic System, highlighting its significant advancements and potential impact in the medical technology sector.
- Increased Market Adoption: Since its full market release in April 2026, the LIBERTY System has been widely utilized at leading academic centers across states like New York, Pennsylvania, and Florida, indicating its growing importance in endovascular procedures.
- Unique Technology: LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system designed for precise vascular navigation, aiming to enhance safety and efficiency while reducing radiation exposure and physical strain during procedures.
- Strategic Future Focus: CEO Harel Gadot emphasized that Microbot Medical will continue to focus on expanding the adoption of the LIBERTY System and executing its commercial strategy, demonstrating a strong commitment to shaping the future of endovascular care through innovation.
See More
Microbot Medical Expands Footprint in Northeast U.S.
- Market Expansion: Microbot Medical's adoption of the LIBERTY System by a Pennsylvania academic center marks a significant increase in its market penetration in the Northeast U.S., now boasting multiple hospital clients across seven states, reflecting the effectiveness of its commercial efforts.
- Growing Customer Base: The new client operates multiple hospitals and multispecialty centers in Pennsylvania and New Jersey, becoming the second customer with facilities spanning two states, indicating the company's increasing influence in densely populated markets and further solidifying its market position.
- Sales Territory Plans: Following the full market release of the LIBERTY System, the company plans to expand its sales territory to the West Coast, demonstrating confidence in future growth and strategic positioning in new markets.
- Federal Healthcare System Collaboration: The agreement to expand access to the LIBERTY System across U.S. federal healthcare systems, including those serving veterans and military patients, further enhances adoption rates among existing and new accounts, supporting the company's commercialization strategy.
See More
Microbot Medical Expands LIBERTY System Adoption in Michigan
- Market Expansion: Microbot Medical announced the adoption of its LIBERTY® Endovascular Robotic System by one of the largest healthcare systems in Michigan, marking a significant acceleration in the system's rollout across the Midwest U.S., reflecting growing recognition among health systems for advanced robotic solutions.
- Increasing Demand: With approximately 2.5 million peripheral endovascular procedures performed annually in the U.S., Microbot believes this ongoing market expansion indicates a rising demand for integrating robotic technology into routine vascular care, suggesting strong future growth potential for the company.
- Regulatory Approval: The LIBERTY System recently received regulatory approval from the Israeli Ministry of Health's AMAR Division, allowing the company to market and sell the system in Israel, which not only broadens its market reach but also enhances its global business flexibility.
- Strategic Positioning: CEO Harel Gadot stated that the expansion of the LIBERTY System enhances procedural workflow efficiency while supporting physician well-being, further solidifying Microbot Medical's market position in the medical robotics sector.
See More
Microbot Medical Secures First Customer in North Carolina
- Market Expansion: Microbot Medical has successfully secured its first customer in North Carolina, marking a significant broadening of its LIBERTY® Endovascular Robotic System's penetration in the Southeast and Mid-Atlantic regions, indicating strong growth potential in the medical device sector.
- Client Network: The new customer operates a multi-hospital network that provides state-of-the-art patient care across the state, further validating the unique advantages of the LIBERTY system and likely attracting more healthcare systems to consider its adoption.
- Commercial Strategy Execution: The addition of the North Carolina account is viewed as a significant advancement in Microbot's ongoing commercial strategy, with CEO Harel Gadot noting a rapid increase in new accounts following the full market release, reflecting robust market demand.
- Future Outlook: The company plans to penetrate other major metropolitan markets, aiming to attract leading academic institutions in the U.S. to adopt the LIBERTY system, which is expected to drive future revenue growth and enhance market share.
See More
